首页> 美国卫生研究院文献>Pharmaceutics >Enhancement of Aqueous Solubility and Dissolution of Celecoxib through Phosphatidylcholine-Based Dispersion Systems Solidified with Adsorbent Carriers
【2h】

Enhancement of Aqueous Solubility and Dissolution of Celecoxib through Phosphatidylcholine-Based Dispersion Systems Solidified with Adsorbent Carriers

机译:通过吸附剂载体固化的磷脂酰胆碱分散体系提高塞来昔布的水溶解度和溶解度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed to design phosphatidylcholine (PC)-based solid dispersion (SD) systems for enhancing the apparent aqueous solubility and dissolution of celecoxib (CLC), a selective cyclooxygenase-2 inhibitor with a highly hydrophobic property. Although PC-based dispersion formulations considerably increased solubilities of CLC, the lipidic texture of PC was not appropriate as a solid dosage form for oral administration of CLC. To mask the lipidic texture of PC-based matrices, Neusilin® US2, an adsorbent material with a porous structure and large surface area widely used in the pharmaceutical industry, was employed and thereby fully powderized PC-based dispersion formulations could be fabricated. However, PC matrices containing CLC strongly adsorbed to the pores of Neusilin® US2 was not able to be rapidly released. To address this problem, different hydrophilic materials were examined to promote the release of the CLC-dispersed PC matrices from Neusilin® US2. Among tested hydrophilic materials, croscarmellose sodium was the most suitable to facilitate fast drug dissolution from Neusilin® US2 particles, showing significantly enhanced apparent aqueous solubility and dissolution behavior of CLC. Through differential scanning calorimetry, X-ray diffraction, and Fourier transform infrared spectroscopy (FT-IR) analysis, a considerably reduced crystallinity of CLC dispersed in the PC-based dispersion formulations was demonstrated. The PC-based SD formulations developed in this study would be useful for improving the oral bioavailability of poorly soluble drugs such as CLC.
机译:这项研究旨在设计基于磷脂酰胆碱(PC)的固体分散体(SD)系统,以增强表面活性剂塞来昔布(CLC)的表观水溶性和溶解性,塞来昔布(CLC)是一种具有高度疏水性的选择性环氧化酶2抑制剂。尽管基于PC的分散液配方大大提高了CLC的溶解度,但PC的脂质结构并不适合作为口服CLC的固体剂型。为了掩盖PC基基质的脂质质地,采用了Neusilin ® US2(一种广泛用于制药行业的具有多孔结构和大表面积的吸附材料),从而将PC基分散体完全粉化可以制造配方。但是,含有CLC的PC基质强烈吸附在Neusilin ®sup2US2的孔中,不能快速释放。为了解决这个问题,研究了不同的亲水性材料以促进从Neusilin ® US2释放CLC分散的PC基质。在测试的亲水性材料中,交联羧甲基纤维素钠最适合于促进Neusilin ® US2颗粒的快速药物溶解,表现出明显增强的表观水溶性和CLC溶解行为。通过差示扫描量热法,X射线衍射和傅立叶变换红外光谱(FT-IR)分析,证实了分散在基于PC的分散体配方中的CLC的结晶度大大降低。在这项研究中开发的基于PC的SD配方将有助于改善难溶性药物(如CLC)的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号